Syngene International Ltd vs Tejnaksh Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Syngene International Ltd is ₹ 397.4 as of 30 Oct 11:21 . The P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 yearsThe P/E Ratio of Tejnaksh Healthcare Ltd changed from 36 on March 2021 to 19.9 on March 2026 . This represents a CAGR of -9.41% over 6 years The Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 yearsThe Market Cap of Tejnaksh Healthcare Ltd changed from ₹ 73.94 crore on March 2021 to ₹ 24.23 crore on March 2026 . This represents a CAGR of -16.97% over 6 years The revenue of Syngene International Ltd for the Sep '26 is ₹ 860.7 crore as compare to the Jun '26 revenue of ₹ 761.3 crore. This represent the growth of 13.06% The revenue of Tejnaksh Healthcare Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 2.75 crore. This represent the decline of -100% The ebitda of Syngene International Ltd for the Sep '26 is ₹ 168.7 crore as compare to the Jun '26 ebitda of ₹ 102.6 crore. This represent the growth of 64.42% The ebitda of Tejnaksh Healthcare Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0.79 crore. This represent the decline of -100% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ 32.2 crore over 10 quarters. This represents a CAGR of -28.96% The net profit of Tejnaksh Healthcare Ltd changed from ₹ 0.6 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of -100.00% The Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 yearsThe Dividend Payout of Tejnaksh Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

About Tejnaksh Healthcare Ltd

Tejnaksh Healthcare Limited was incorporated in Mumbai on 18 February, 2008 as a Private Limited Company and converted into Public Limited Company with effect from 10 March, 2015 issued by the Registrar of Companies, Mumbai, Maharashtra.
Tejnaksh runs an Institute of Urology, an ISO certified the international level Urology hospital, located in Dhule, Maharashtra.
It provides a complete range of services from consultations and investigations to treatment for Urology.
The main objective of Hospital namely Institute of Urology is to provide the people of Khandesh region of Maharashtra, the services of a super specialty hospital at an affordable rate. Initiated with a vision to strengthen healthcare in rural India, the Company started its journey from Institute of Urology, a state of the art flagship, kidney care center in Dhule in the year 2003.

FAQs for the comparison of Syngene International Ltd and Tejnaksh Healthcare Ltd

Which company has a larger market capitalization, Syngene International Ltd or Tejnaksh Healthcare Ltd?

Market cap of Syngene International Ltd is 16,251 Cr while Market cap of Tejnaksh Healthcare Ltd is 26 Cr

What are the key factors driving the stock performance of Syngene International Ltd and Tejnaksh Healthcare Ltd?

The stock performance of Syngene International Ltd and Tejnaksh Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syngene International Ltd and Tejnaksh Healthcare Ltd?

As of November 1, 2026, the Syngene International Ltd stock price is INR ₹402.6. On the other hand, Tejnaksh Healthcare Ltd stock price is INR ₹12.83.

How do dividend payouts of Syngene International Ltd and Tejnaksh Healthcare Ltd compare?

To compare the dividend payouts of Syngene International Ltd and Tejnaksh Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.